CTAD 2024 - 17th Clinical Trials on Alzheimer's Disease Congress

Selected poster presentations:

LP050
Development of Blood-Based pTau217 Assay Using a Novel Ultrasensitive Single-Molecule Counting Technology

Kumiko Hamano¹, Yukina Kawada¹, Masayasu Imaizumi¹, Gipshu Dave², Ko Kobayashi², Mariya Soban², Hayato Kimura², Kazushige Moriyama¹, Katsumi Aoyagi¹, Frank Zaugg², Peter Wagner², Johanna Sandlund², Renee Tobias², Valerie Brachet^2
1Fujirebio, Inc., - Tokyo (Japan), ²Fluxus, Inc. - Sunnyvale (United States)

LP051
Analytical Performance of the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio

Luna Buitrago¹, Francesca I. De Simone¹, Natalya Benina¹, Rachel R. Radwan¹, Jessica Junfola¹, Andie Graney¹, Natalie Goepfert¹, Eric Jones¹, M. Craig Miller², Abhay Moghekar³, William T. Hu⁴, Diana Dickson^1
1Fujirebio Diagnostics Inc. - Malvern, Pa (United States), ²Statistical Consultant, Fujirebio Diagnostics Inc. - Quakertown, Pa (United States), ³Department of Neurology, John Hopkins School of Medicine - Baltimore, Md (United States), ⁴Department of Neurology, Rutgers-Robert Wood Johnson Medical School and Center for Healthy Aging, Rutgers Institute for Health, Health Care Policy, and Aging Research - New Brunswick, Nj (United States)

LP053
Impact of preanalytical factors on the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio

Luna Buitrago¹, Francesca I. De Simone¹, Natalya Benina¹, Rachel R. Radwan¹, Amanda Calabro¹, Jessica Junfola¹, Natalie Goepfert¹, Abhay Moghekar², Diana Dickson^1
1Fujirebio Diagnostics Inc. - Malvern, Pa (United States), ²Department of Neurology, Johns Hopkins School of Medicine - Baltimore, Md (United States)

LP055
Clinical performance of the Lumipulse G pTau 217/β-Amyloid 1-42 Plasma Ratio

Francesca I. De Simone¹, Luna Buitrago¹, Natalya Benina¹, Jessica Junfola¹, Stephen Menkes¹, James Koch¹, Douglas Hawkins², James Rock³, Oskar Hansson^4,5, Erik Stomrud^4,5, Richard C. Mohs⁶, Elaine Peskind^7,8, Jefferson Kinney⁹, Sterling Johnson¹⁰, Rachel R. Radwan^1
1Fujirebio Diagnostics Inc. - Malvern, Pa (United States), ²Scottsdale Scientific LLC - Austin, Tx (United States), ³AriBio Co., Ltd - La Jolla, Ca (United States), ⁴Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University - Lund (Sweden), ⁵Memory Clinic, Skane University Hospital - Malmo (Sweden), 6Global Alzheimer’s Platform Foundation - Washington, Dc (United States), ⁷Veterans Affairs Northwest Network Mental Illness Research, Education, and Clinical Center, Veteran Affairs Puget Sound Health Care System - Seattle, Wa (United States), ⁸Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine - Seattle, Wa, ⁹Department of Brain Health, University of Nevada - Las Vegas, Nv (United States), ¹⁰Wisconsin Alzheimer’s Disease Research Center, University of Wisconsin-Madison School of Medicine and Public Health - Madison, Wi (United States)

LP066
Novel β-synuclein specific assays

Julie Goossens¹, Charlotte De Rocker¹, Sherif Bayoumy², Megan De Pauw¹, Shreaysee Das¹, Wiesje Van Der Flier², Inge M. Verberk², Charlotte Teunissen², Eugeen Vanmechelen^1
1ADx NeuroSciences - Gent (Belgium), ²Amsterdam UMC - Amsterdam (Netherlands)

LP068
Plasma pTau-217 versus plasma pTau-217/Aβ1-42 ratio performance in predicting amyloid positivity compared to CSF Aβ42/40 ratio or PET in a screening cohort from a phase 3 registration study: Implications for a triage model

Sharon Sha¹, James Rock², Fred Kim², Rachel Radwan³, Francesca I. De Simone³, Natalya Benina³, Douglas Hawkins^4
1Neurology & Neurological Sciences, Stanford University - Palo Alto (United States), ²AriBio Co., Ltd. - San Diego (United States), ³Fujirebio Diagnostics, Inc. - Malvern (United States), ⁴Scottsdale Scientific LLC - Austin (United States)

P104 – ADx NeuroSciences
Plasma pTau181 and pTau217 similarly predict asymptomatic amyloid accumulation with performances comparable to amyloid-PET

Steffi De Meyer¹, Jolien Schaeverbeke¹, Emma Luckett¹, Elena Blujdea², Patrick Dupont¹, Koen Van Laere³, Jeroen Vanbrabant⁴, Erik Stoops⁴, Eugeen Vanmechelen⁴, Guglielmo Di Molfetta⁵, Henrik Zetterberg⁵, Nicholas Ashton⁵, Charlotte Teunissen⁶, Koen Poesen³, Rik Vandenberghe^3
1KU Leuven - Leuven (Belgium), ²UMC Amsterdam - Amsterdam (Netherlands), ³UZ Leuven - Leuven (Belgium), ⁴ADx NeuroSciences - Ghent (Belgium), ⁵Sahlgrenska Academy - Mölndal (Sweden), ⁶UMC Amsterdam - Amsterdam (Sweden)

P111 – ADx NeuroSciences
Cerebrospinal fluid levels of VAMP-2 and SNAP-25 are associated with executive function in dementia with Lewy bodies, an effect that is cofounded by Alzheimer comorbidity

Alba Cervantes González^1,2, Julie Goosens³, Nele Dewit⁴, Laia Lidón^1,2, Danna Perlaza^1,2, Juan Fortea^1,2, Daniel Alcolea^1,2, Alberto Lleo^1,2, Eugeen Vanmechelen³, Olivia Belbin^1,2
1Sant Pau Memory Unit, Neurology Department and IIB-Sant Pau, Hospital de La Santa Creu I Santa Pau, Universitat Autonoma de Barcelona - Barcelona (Spain), ²Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), - Madrid (Spain), ³ADx NeuroSciences NV, Zwijnaarde - Ghent (Belgium), ⁴Medpace Reference Laboratories (A.A.), Flow Cytometry Unit - Louvain (Belgium)

P134
Advancing Detection of Neurological Biomarkers in Blood Using a Novel Ultrasensitive Single Molecule Counting Technology

Renee Tobias¹, Peter Wagner¹, Johanna Sandlund¹, Kazushige Moriyama², Masayasu Imaizumi², Yukina Kawada², Kumiko Hamano², Frank Zaugg¹, Gipshu Dave¹, Daigo Inaoka¹, Hayato Kimura¹, Ko Kobayashi¹, Valerie Brachet^1
1Fluxus, Inc. - Sunnyvale (United States), ²Fujirebio, Inc. - Tokyo (Japan)